Cytosorbents (NASDAQ:CTSO) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO - Free Report) in a research note issued to investors on Saturday morning. The firm issued a hold rating on the medical research company's stock.

Several other equities research analysts have also commented on the stock. EF Hutton Acquisition Co. I raised shares of Cytosorbents to a "strong-buy" rating in a research note on Monday, July 29th. HC Wainwright reissued a "neutral" rating and issued a $1.00 price objective on shares of Cytosorbents in a research note on Wednesday, August 14th.

Cytosorbents Stock Performance

NASDAQ:CTSO opened at $1.00 on Friday. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.12 and a quick ratio of 1.71. The business has a fifty day simple moving average of $1.15 and a two-hundred day simple moving average of $1.00. Cytosorbents has a 1 year low of $0.70 and a 1 year high of $2.15. The company has a market capitalization of $54.43 million, a P/E ratio of -1.89 and a beta of 0.51.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.01. Cytosorbents had a negative return on equity of 131.84% and a negative net margin of 68.70%. The company had revenue of $9.89 million during the quarter, compared to analyst estimates of $9.73 million. During the same quarter last year, the company earned ($0.14) earnings per share. On average, analysts expect that Cytosorbents will post -0.31 earnings per share for the current year.

Institutional Investors Weigh In On Cytosorbents

Several institutional investors and hedge funds have recently added to or reduced their stakes in CTSO. Atomi Financial Group Inc. purchased a new stake in Cytosorbents during the third quarter worth about $51,000. CM Management LLC increased its stake in shares of Cytosorbents by 3.0% during the second quarter. CM Management LLC now owns 850,000 shares of the medical research company's stock worth $598,000 after buying an additional 25,000 shares during the period. Sargent Investment Group LLC increased its stake in shares of Cytosorbents by 4.9% during the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company's stock worth $1,008,000 after buying an additional 67,181 shares during the period. Finally, Avenir Corp increased its stake in shares of Cytosorbents by 4.0% during the first quarter. Avenir Corp now owns 3,172,696 shares of the medical research company's stock worth $3,014,000 after buying an additional 121,294 shares during the period. Hedge funds and other institutional investors own 32.87% of the company's stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.